U.S. markets open in 1 hour 24 minutes
  • S&P Futures

    3,430.25
    -2.00 (-0.06%)
     
  • Dow Futures

    28,169.00
    -13.00 (-0.05%)
     
  • Nasdaq Futures

    11,636.00
    -24.75 (-0.21%)
     
  • Russell 2000 Futures

    1,613.40
    -1.40 (-0.09%)
     
  • Crude Oil

    40.99
    -0.71 (-1.70%)
     
  • Gold

    1,920.10
    +4.70 (+0.25%)
     
  • Silver

    25.07
    +0.09 (+0.36%)
     
  • EUR/USD

    1.1855
    +0.0027 (+0.23%)
     
  • 10-Yr Bond

    0.7970
    0.0000 (0.00%)
     
  • Vix

    29.97
    +0.79 (+2.71%)
     
  • GBP/USD

    1.3059
    +0.0112 (+0.87%)
     
  • USD/JPY

    104.8400
    -0.6300 (-0.60%)
     
  • BTC-USD

    12,326.55
    +1,269.54 (+11.48%)
     
  • CMC Crypto 200

    247.44
    +8.53 (+3.57%)
     
  • FTSE 100

    5,818.52
    -70.70 (-1.20%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Oncternal Therapeutics to Present at Stifel Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT.

A live webcast of the presentation will be available online via a link from the investor relations page of the Company’s website at www.oncternal.com, and the webcast will be archived there for at least 30 days following the event.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and TK216, an investigational small-molecule compound that is designed to inhibit E26 transformation specific (ETS) family oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191111005083/en/